You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CD4 T cells

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Psoriasis Trial in Sohag (skin biopsy)

Not yet recruiting
  • Psoriasis
  • skin biopsy
  • Sohag, Egypt
    Sohag university Hospital
Sep 21, 2023

Hiv Trial in Philadelphia (Autologous CD4 T-Cells)

Completed
Has Results
  • Hiv
  • Autologous CD4 T-Cells
  • Philadelphia, Pennsylvania
    University of Pennsylvania
Nov 13, 2022

Aviremic HIV-1 in CD4+ T Cells of Adults Undergoing Treatment

Recruiting
  • HIV-1-infection
  • Bioclinical evaluation
  • Nîmes, France
    CHU de Nimes
Jul 28, 2022

Pancreatic Ductal Adenocarcinoma, NSCLC, Colorectal Cancer Trial (AFNT-211)

Not yet recruiting
  • Pancreatic Ductal Adenocarcinoma
  • +4 more
  • (no location specified)
Oct 23, 2023

HIV Trial in Cincinnati (SB-728-T, Expanded unmodified autologous CD4+ T cells)

Active, not recruiting
  • HIV Infections
  • SB-728-T
  • Expanded unmodified autologous CD4+ T cells
  • Cincinnati, Ohio
    University of Cincinnati
Jan 1, 2022

T-cell Lymphoma, T-cell Leukemia Trial in Indianapolis (CD4CAR)

Recruiting
  • T-cell Lymphoma
  • T-cell Leukemia
  • CD4CAR
  • Indianapolis, Indiana
    Indiana University Melvin and Bren Simon Comprehensive Cancer Ce
Dec 16, 2022

HPV 16+ Recurrent or Metastatic Cancer Trial (CD8 reduced peripheral blood cells taken from related donors vaccinated against

Not yet recruiting
  • HPV 16+ Recurrent or Metastatic Cancer
  • CD8 reduced peripheral blood cells taken from related donors vaccinated against HPV16
  • Non-myeloablative allogeneic bone marrow transplant from related donors vaccinated against HPV16
  • (no location specified)
Jun 27, 2022

HIV Trial in Stanford (Ritonavir, gp160 Vaccine (Immuno-AG), Stavudine)

Completed
  • HIV Infections
  • Stanford, California
    Stanford CRS
Oct 27, 2021

Juvenile Myelomonocytic Leukemia, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Undifferentiated Leukemia Trial in

Suspended
  • Juvenile Myelomonocytic Leukemia
  • +27 more
  • CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR
  • +2 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jan 11, 2023

Hodgkin Lymphoma, Relapse, Refractory Trial in Chapel Hill (Chemotherapy, Cell infusion)

Not yet recruiting
  • Hodgkin Lymphoma
  • +2 more
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center
Oct 13, 2023

Metastatic Colorectal Adenocarcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma Trial in

Not yet recruiting
  • Metastatic Colorectal Adenocarcinoma
  • +5 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Sep 12, 2023

T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma, Acute Myeloid Leukemia Trial in Beijing, Shenzhen,

Recruiting
  • T-cell Acute Lymphoblastic Leukemia
  • +3 more
  • Universal CD7-specific CAR gene-engineered T cells
  • Beijing, Beijing, China
  • +2 more
Aug 17, 2023

T Cell Lymphoma, T-cell Leukemia Trial in Beijing (Efficacy of LCAR-T2C CAR-T cells)

Terminated
  • T Cell Lymphoma
  • T-cell Leukemia
  • Efficacy of LCAR-T2C CAR-T cells
  • Beijing, Beijing, China
  • +1 more
Aug 12, 2022

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Seattle (biological, drug, procedure)

Completed
Has Results
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 3, 2022

B Cell Malignancies Trial in Beijing, Shenzhen, Haikou (Universal CD19-specific CAR gene-engineered T cells)

Recruiting
  • B Cell Malignancies
  • Universal CD19-specific CAR gene-engineered T cells
  • Beijing, Beijing, China
  • +2 more
Aug 8, 2023

HIV-1 Infections Trial in Washington (HAART, T cells)

Completed
  • HIV-1 Infections
  • Washington, District of Columbia
    Walter Reed Army Medical Center
Aug 17, 2022

Interleukins in Periodontal Disease Progression

Recruiting
  • Periodontitis
  • Gingivitis
  • Flow Cytometric Detection of Regulatory T Cells and Cytokines analysis by ELISA
  • Assiut, Asyut, Egypt
    Department of oral medicine, Periodontology, Oral diagnosis and
Nov 16, 2023

Urinary T Cell Biomarker for Prediction in Lupus Nephritis

Active, not recruiting
  • Lupus Nephritis
  • Flow cytometry analysis of urine samples
  • Berlin, Germany
  • +1 more
Mar 8, 2022

Leukemia, Myeloid, Acute Trial (CD33KO-HSPC; CART33)

Not yet recruiting
  • Leukemia, Myeloid, Acute
  • CD33KO-HSPC; CART33
  • (no location specified)
Jul 13, 2023

Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8 Trial in Duarte

Not yet recruiting
  • Castration-Resistant Prostate Carcinoma
  • +2 more
  • Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes
  • +7 more
  • Duarte, California
    City of Hope Medical Center
Apr 5, 2023

Cancer Disease Trial in Shenzhen (bi-4SCAR PSMA/CD70 T cells)

Recruiting
  • Cancer Disease
  • bi-4SCAR PSMA/CD70 T cells
  • Shenzhen, Guangdong, China
    Shenzhen Geno-immune Medical Institute
Jun 25, 2022

Cancer Disease Trial in Shenzhen (bi-4SCAR GD2/CD70 T cells)

Recruiting
  • Cancer Disease
  • bi-4SCAR GD2/CD70 T cells
  • Shenzhen, Guangdong, China
    Shenzhen Geno-immune Medical Institute
Jun 25, 2022

Malignant Disease Trial in Shenzhen (bi-4SCAR GD2/CD56 T cells)

Recruiting
  • Malignant Disease
  • bi-4SCAR GD2/CD56 T cells
  • Shenzhen, Guangdong, China
    Shenzhen Geno-immune Medical Institute
Jun 25, 2022

B Cell Malignancies Trial in Shenzhen (bi-4SCAR CD19/70 T cells)

Recruiting
  • B Cell Malignancies
  • bi-4SCAR CD19/70 T cells
  • Shenzhen, Guangdong, China
    Shenzhen Geno-immune Medical Institute
Jun 28, 2022

B Cell Malignancies Trial in Shenzhen (bi-4SCAR CD19/22 T cells)

Recruiting
  • B Cell Malignancies
  • bi-4SCAR CD19/22 T cells
  • Shenzhen, Guangdong, China
    Shenzhen Geno-immune Medical Institute
Jun 21, 2022